Picture Berlin Partner BIO 2024 International Convention San Diego 650x100px
Document › Details

Core Biogenesis SAS. (3/29/22). "Press Release: Core Biogenesis Raises €10M from XAnge and Blue Horizon Ventures to Accelerate Treatment of Cancer and Neurodegenerative Diseases".

Organisations Organisation Core Biogenesis SAS
  Organisation 2 Blue Horizon Ventures (LU)
Products Product BIOTECH
  Product 2 venture capital
Index terms Index term Core Biogenesis–SEVERAL: investment, 202203 financing round Series A €10m led by XAnge + Blue Horizon Ventures
  Index term 2 Core Biogenesis–SEVERAL: investment, 202012 seed financing round €2.6m led by XAnge
Persons Person Reeber, Alexandre (Core Biogenesis 202204 CEO + Co-Founder)
  Person 2 du Peloux, Alexis (Siparex 202203 Principal at XAnge)

> Founded in May 2020, Core Biogenesis produces key molecules for cell therapy that accelerate the development of cells involved in the treatment of these diseases.

> After a first round of financing of €2.6M in December 2020, the Strasbourg-based start-up, which operates at the crossroads of the BioTech and Health Tech worlds, is raising funds that will enable it to industrialize its bioproduction technology.

> This cell therapy market is expected to increase tenfold within ten years.

An innovative technology, less expensive and which solves the problem of the speed of production of the cells.

Core Biogenesis produces recombinant cytokines and growth factors on a large scale using plants. The function of these molecules is to proliferate and differentiate cells. The growth factors allow to switch from one cell type to another during their transformation.

These molecules are key ingredients in the manufacturing of cell and gene therapies, which represent an immense hope for the treatment of neurodegenerative and cardiovascular diseases and a number of cancers.

Today, despite this potential and the high stakes of cell and gene therapies, their development and adoption remain limited because the manufacturing ingredients are expensive. Core Biogenesis solves this problem. Its unique technology allows it to produce these key molecules at a reduced cost and in quantities that are many times greater than what is currently available. This makes these therapies more financially accessible, facilitating their democratization among patients.

A fundraising of 10 million euros with two objectives.

To go to an industrial scale with a factory under construction in the Grand Est...

Core Biogenesis is currently testing samples of its molecules with several clients in the biopharmaceutical industry and research laboratories. The company will multiply these collaborations with its customers and partners until the commercialization of its molecules in early 2023. Its first objective is to move its molecule production from a laboratory scale to an industrial scale.

"After several months of R&D and laboratory production, we are starting a new phase with the industrialization of our bioproduction technology. In 2021, the cell therapy market was estimated at $9.2 billion and will grow exponentially over the next few years to reach $65 billion by 2027. Our goal is to be the world leader in this new market at the crossroads of the healthcare, biopharmaceutical and biotech sectors," said Alexandre Reeber and Chouaib Meziadi, co-founders of Core Biogenesis.

The construction of Core Biogenesis' first biomolecule production facility in Strasbourg will pave the way for this large-scale production. This will enable it to launch its large-scale production and reach the market within a dozen months and begin serving its customers in the biopharmaceutical industry who are developing cell-based therapies.

...and recruit

To support this growth, Core Biogenesis will recruit ten scientific and technical profiles over the next six months, bringing its total number of employees to 30.

Alexis du Peloux, Principal at XAnge comments: "Because our conviction is stronger than ever on the subject, and thanks to an excellent execution by Alexandre, Chouaib and their team, we are delighted to lead the Series A round one year after leading the seed round. This round of financing will allow us to accelerate R&D, production and commercial development. We believe that Core Biogenesis can eventually become a world leader thanks to its disruptive technology and we are delighted to support them in this ambition.

Friederike Grosse-Holz, Investment Director at Blue Horizon Ventures said: "Core Biogenesis' highly scalable and cost-effective production approach can help unlock the commercialization of cell-based therapies, enabling exceptional positive impact. We are proud and excited to join Alexandre and his team on this exciting journey. "

About Core Biogenesis:

Founded in May 2020 by Dr. Chouaib Meziadi and Alexandre Reeber, Core Biogenesis produces key molecules for cell therapy that accelerate the development of cells involved in the treatment of neurodegenerative and cardiovascular diseases and certain cancers. In December 2020, the startup raised €2.6 million in Seed from XAnge, Entrepreneur First, Plug and Play and several Business Angels. In March 2022 it completed a 2nd round of €10M in Series A from XAnge, Blue Horizon Ventures, Entrepreneur First and Business Angels. Core Biogenesis was Grand Prize winner of the national i-Lab BPI France competition in 2021.

Press contact:

Estelle Monraisse - Alter'Com Conseil
06 60 41 81 52 -

Record changed: 2024-03-30


Picture Berlin Partner Voices Robinson Data for Precision Medicine 650x200px

More documents for Core Biogenesis SAS

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner Top News Healthtech Company Mika 650x300px

» top